Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 3 (Dan-NICAD 3)
In a cohort of symptomatic patients referred to coronary computed tomography angiography (CCTA), the investigators aim is:
- To investigate and compare the diagnostic precision of Rubidium Positron Emission Tomography (Rb PET) and 15O-water PET (15O-water PET) in patients where CCTA does not exclude obstructive coronary artery disease (CAD) using invasive coronary angiography with fractional flow reserve (ICA-FFR) as reference standard.
- To study the diagnostic accuracy and prognostic value of computed tomography fractional flow reserve (CT-FFR) in patients where CCTA does not exclude obstructive CAD with ICA-FFR as reference standard.
- To validated a pre-test probability model including genetic and circulating biomarkers.
- To identify and characterize genetic risk variants and circulating biomarkers importance in developing CAD.
- To evaluate the bone mineral density in the hip and spine and correlate this to the degree of vascular calcification.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
CCTA has become the preferred diagnostic modality for symptomatic patients with low to intermediate risk of CAD. Of the patients examined, CCTA exclude cardiovascular disease in 70-80% with an excellent negative predictive value of more than 95%. Having a low positive predictive value, however, CCTA often overestimates the severity of CAD, especially in patients with moderate to severe coronary calcification. Following CCTA, patients are hence unnecessarily tested using golden standard ICA-FFR. These ICAs often show no obstructive coronary stenosis and are therefore not followed by revascularization. The issues outlined raises the question of whether it is possible (1) to make a more precise risk stratification and consequently better selection of patients prior to CCTA and (2) to reduce the number of patients referred for unnecessary ICAs following CCTA.
In patients with suspicion of coronary stenosis detected by CCTA, current guidelines recommend verification of myocardial ischemia. Dan-NICAD 3 investigate the diagnostic accuracy of advanced non-invasive myocardial perfusion imaging tests; Rb PET and 15O-water PET. These examinations have shown a high diagnostic accuracy in symptomatic patients with high risk of ischemic heart disease. However, the diagnostic accuracy is not investigated in patients as follow-up after CCTA. In addition, microcirculation may impact the correlation between PET and ICA-FFR which this study will investigate further.
An alternative way to increase the diagnostic accuracy of CCTA and thus avoid unnecessary downstream testing using ICA is to utilize the ability to extract physiological information from the anatomical CCTA images. CT-FFR has in previous studies shown promising results. In addition, calculated estimation of microcirculatiory function is under development and this study will validated these algorithms. Furthermore, the prognostic value of CT-FFR is unknown and will be tested in the pooled cohort of Dan-NICAD 1, 2 and 3.
Obtained during ICA, quantitative flow ratio (QFR) is a novel wire-free approach for fast computation of FFR with potential to increase the global use of physiological lesion assessment. QFR is superior to traditional assessment of intermediate coronary lesions based on quantitative coronary analysis of ICA. However, disagreement between ICA-FFR and QFR has been identified in up to 20% of all measurements. QFR will be validated compared to PET and ICA-FFR.
Typ studie
Zápis (Očekávaný)
Kontakty a umístění
Studijní místa
-
-
-
Herning, Dánsko, 7400
- Nábor
- Gødstrup Hospital
-
Kontakt:
- Simon Winther, MD, PhD
- E-mail: simwin@rm.dk
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
- Inclusion Criteria:
Patients with an indication for CCTA. Qualified patients who have signed a written informed consent form.
- Exclusion Criteria:
Demography and co-existing cardiac morbidity specific: Age below 30 years, patients having a donor heart, a mechanic heart, or mechanical heart pump, suspicion acute coronary syndrome or previous revascularization.
CCTA: Pregnant women, including women who are potentially pregnant or lactating, reduced kidney function, with an estimated glomerular filtration rate (eGFR) < 40 mL/min or allergy to X-ray contrast medium.
PET: contra-indication for adenosine (severe asthma, advanced atrioventricular block, or critical aorta stenosis).
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Cohort
Participants consenting to the study will undergo: a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for > 10 years Patients with suspicion of coronary stenosis detected by CCTA will after undergo: b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR) |
Head to head comparison with invasive FFR as reference.
Adjustment for abnormal microcirculation
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Diagnostic accuracy of Rb PET and 15-O PET
Časové okno: ICA: 4 weeks after inclusion
|
Head-to-head comparison using ICA-FFR as reference standard stratified for CFR
|
ICA: 4 weeks after inclusion
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Diagnostic accuracy of QFR vs. ICA-FFR
Časové okno: ICA: 4 weeks after inclusion
|
Head-to-head comparison using ICA-FFR as reference standard
|
ICA: 4 weeks after inclusion
|
|
Pre-test probability model of CAD
Časové okno: ICA: 4 weeks after inclusion
|
Advanced pre-test probability model of CAD included clinical information, genetic and circulating biomarkers
|
ICA: 4 weeks after inclusion
|
|
Diagnostic accuracy of QFR
Časové okno: ICA: 4 weeks after inclusion
|
Head-to-head comparison using ICA-FFR as reference standard
|
ICA: 4 weeks after inclusion
|
|
Diagnostic accuracy of CT-FFR
Časové okno: ICA: 4 weeks after inclusion
|
Head-to-head comparison with PET using ICA-FFR as reference standard
|
ICA: 4 weeks after inclusion
|
|
Effect of reduced myocardial perfusion defect on symptoms of angina pectoris
Časové okno: Re-PET: 12 months after inclusion
|
12 months re-PET investigation will by used for estimation of reduction of myocardial perfusion defect size which will be correlated with symptoms of angina pectoris 3 and 12 mdr.
after ICA
|
Re-PET: 12 months after inclusion
|
|
Prognostic value of clinical, biomarker, genetic information
Časové okno: Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
|
Prognotic models will be developed based on machine learning algorithms
|
Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
|
|
Prognostic value of clinical markers, CCTA, Rb PET, 15O-water PET, CT-FFR and QFR
Časové okno: Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
|
Prognotic models will be developed based on machine learning algorithms
|
Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
|
|
Predictive models of obstructive CAD
Časové okno: ICA: 4 weeks after inclusion
|
Development of pre-test probability models of obstructive CAD at ICA
|
ICA: 4 weeks after inclusion
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Simon Winther, MD, PhD, Hospital Unit West, Herning, Denmark
Publikace a užitečné odkazy
Obecné publikace
- Nissen L, Winther S, Isaksen C, Ejlersen JA, Brix L, Urbonaviciene G, Frost L, Madsen LH, Knudsen LL, Schmidt SE, Holm NR, Maeng M, Nyegaard M, Botker HE, Bottcher M. Danish study of Non-Invasive testing in Coronary Artery Disease (Dan-NICAD): study protocol for a randomised controlled trial. Trials. 2016 May 26;17(1):262. doi: 10.1186/s13063-016-1388-z.
- Rasmussen LD, Winther S, Westra J, Isaksen C, Ejlersen JA, Brix L, Kirk J, Urbonaviciene G, Sondergaard HM, Hammid O, Schmidt SE, Knudsen LL, Madsen LH, Frost L, Petersen SE, Gormsen LC, Christiansen EH, Eftekhari A, Holm NR, Nyegaard M, Chiribiri A, Botker HE, Bottcher M. Danish study of Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2): Study design for a controlled study of diagnostic accuracy. Am Heart J. 2019 Sep;215:114-128. doi: 10.1016/j.ahj.2019.03.016. Epub 2019 May 1.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- Dan-NICAD 3
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .